Right-To-Try laws have been passed in many states across America, paving the way in theory for gravely ill patients to have the right to try unproven treatments of various kinds, and now there is a serious push underway for a national Right-To-Try law. What is a Right-To-Try law? Typically, these Right-To-Try laws allow for a patient […]
Push for National Right-To-Try Law Raises Concerns in Stem Cell Community Read More »
How is the stem cell and regenerative medicine biotech sector doing these days and does recent news about specific biotechs such as Capricor suggest issues for the sector more broadly? Capricor had bad news earlier this year related to its stem cells for heart disease program and things just took a turn for the worse
Shot to the heart: J&J punts on Capricor & its cardiac stem cell program Read More »
A list of stuff for your weekend reading enjoyment ranging from research pubs to news to commentary. Electrical Stimulation Steers Neural Stem Cells. Way to go UC Davis team; see image at right. Stem cell therapies: medical experts call for strict international rules. A team calls for global efforts. Stem cells in court: historical trends in US
TGIF: Stem cell and science weekend reads Read More »
Stem cell clinical trials have a certain gravitational pull for me as I’m always fascinated by them and since the new Cynata trial is moving forward, I recently did an interview their CEO, Dr. Ross A. Macdonald to find out more. PK: Cynata’s recently initiated clinical trial aims to treat GVHD as have other stem
Cynata stem cell trial update: CEO Ross Macdonald interview Read More »
I’ve seen stem cell clinic ad after ad pop up in the mainstream media in my own hometown in The Sacramento Bee paper, but others are sprouting as well and a friend sent me a particularly striking stem cell advertisement from a recent copy of the San Francisco Chronicle. Not only does this stem cell clinic
FIX IT! SF Chronicle runs striking stem cell clinic ad with coupon Read More »
By Cátia Bandeiras, PhD Student at University of Lisbon, Portugal and Massachusetts Institute of Technology. See tweets from the conference using #ISSCR2017 @apulgarita I just wrapped up my stay at the Annual Meeting of ISSCR 2017, which happened in Boston. I decided to take advantage of the fact that I am living in Boston at
Hunting for computational approaches for stem cells at ISSCR2017 Read More »
In December of each year I make a list of stem cell predictions for the coming year, and I made 20 such predictions for 2017 so I’m wondering how I’m doing so far on these now that it’s June. Below is my work-in-progress scorecard for these so far. Positive news from Asterias on trial for stem cell-based
2017 stem cell predictions: score card at 1/2-way point Read More »
A company called Bioquark reportedly claims it intends to bring back the dead, as in deceased people or at least brain dead people, with stem cells. Or at least awaken their brains. If it works, would those people be like zombies? Is it ethical to experiment in this way on dead people? Bioquark We first
Bioquark “reawaken” the dead with stem cells plan just zombie fodder? Read More »
New human clinical trials using derivatives of pluripotent stem cells in China for Parkinson’s Disease (PD) have raised expectations and some eyebrows. PD is a neurodegenerative condition, sometimes diagnosed or followed by PET scans such as the one at left, characterized by loss of dopaminergic neurons leading to severe and sometimes life-threatening symptoms. Pluripotent stem
How risky are stem cell trials for Parkinson’s beginning in China? Read More »
Is there a proliferating stem cell fake news problem in the biotech world? More broadly, the SEC is cracking down on the mess that is fake biotech news, but what about fake news on stem cell biotechs more specifically? Already in the past year I’ve seen examples of possible stem cell fake news. Hyped press releases (PR)
Stem cell fake news driving biotech investors or vice versa…or what? Read More »